Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

NCT05235438 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Oncology
CTLA4 Haploinsufficiency

Interventions

DRUG: IMM27M

Sponsor

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.